drugset / Trial / NCT04605185
Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study is the single-center, open-label phase I clinical trial to evaluate tolerability, safety and efficacy of Donafenib and JS001 in combination with TCAE in patients with Unresectable Hepatocellular Carcinoma.
Timeline
- Start
- 2021-01-08
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | 100 mg | Oral |
| Subject | Donafenib | Small molecule | 150 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |